![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.
AstraZeneca to present phase III data of roxadustat to treat anaemia from CKD at ASN Kidney Week 2019
AstraZeneca will present pooled efficacy and cardiovascular safety analyses from the phase III clinical programme of roxadustat for the treatment of anaemia from chronic kidney disease (CKD) in non dialysis─dependent...
European Commission approves new indication for Dupixent in chronic rhinosinusitis with nasal polyposis
The European Commission (EC), approved a new indication for Dupixent (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add─on therapy with intranasal corticosteroids
EMA’s safety committee recommends restriction on use of Lemtrada for multiple sclerosis patients
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has recommended restrictions on the use of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple...
EMA validates Vertex’s MAA for elexacaftor, tezacaftor & ivacaftor triple combination treatment in CF
Vertex Pharmaceuticals Limited, a global biotechnology company, announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for the VX─445 (elexacaftor), tezacaftor and...
EMA’s PRAC committee recommends Xeljanz to be used with caution for all patients at high risk of blood clots
A review by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in...
The Financial Times is rolling out subscriber-only podcasts
The Financial Times has expanded its audio strategy to include subscriber-only podcasts, a first for the publisher. The FT has hired its first global head of audio Cheryl Brumley, who will beef up the team of dedicated...
Astellas' Xospata gets European approval as monotherapy for patients with relapsed/refractory AML with FLT3 mutation
Astellas Pharma Inc. announced that the European Commission (EC) has approved the oral once─daily therapy Xospata (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory
Eerste vaccin ter bescherming tegen ebola
Het Europees Medicijnagentschap EMA heeft een positief advies gegeven over het verlenen van een vergunning voor Ervebo. Dit is het eerste vaccin tegen het ebola-virus. “Met dit vaccin zetten we een belangrijke stap in...
Eerste Emerce Update gewijd aan online beveiliging en privacy
De eerste sprekers voor Emerce Update #7: Security Make sure you secure, op 10 december in B. Amsterdam, zijn bekend. Het is de eerste Update van Emerce gewijd aan online beveiliging. Ivana Bartoletti (Gemserv &...
Gilead's ready to spend big on Descovy, filgotinib launches as hep C and Yescarta struggle: CEO
If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches—starting with HIV drug Descovy in PrEP—they don’t need to be, according to...
Novartis gets European approval to update Cosentyx label to include dosing flexibility in ankylosing spondylitis
Novartis, a leader in rheumatology and immuno─dermatology, announced that the European Commission (EC) has approved a label update for the up─titration of Cosentyx (secukinumab) to 300 mg for patients with...
Vertex lands blockbuster triple combo nod for CF drug Trikafta—5 months early
The triple combo era in cystic fibrosis is here thanks to Vertex’ new OK. Five months ahead of schedule, the FDA green-lighted Trikafta for the treatment of CF patients over the age of 12 with either one or two...
Roche’s Tecentriq scores a first-in-class double win in new liver cancer patients
Roche is out in full force with Tecentriq results in liver cancer. The immuno-oncology med, in combination with fellow Roche drug Avastin, not only showed it could beat Bayer’s standard-of-care Nexavar at stalling...
Vind je plek in de massa; maak originele content
Iedere contentmarketeer kent het begrip storytelling. En iedere contentmarketeer wil graag unieke en originele content maken voor zijn of haar opdrachtgever. Maar hoe doe je dat in een tijd waar de socialmedia...
2019 saw the FDA approve more generic drugs than ever before
Fiscal year 2019 was a record-breaking one, according to the FDA. The US regulator smashed its previous total for annual generic drug approvals with 1,171 positive reviews completed that year, comprising 935 approvals...
6 Content Marketing Tips That Will Give You an Aha Moment
A lot of content exists about content marketing. You may wonder how to distill everything you see and hear into action. Pick one of these six great – sometimes contrarian – content marketing lessons. Continue reading →...
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment...
